Literature DB >> 11939261

Comparison of Pgp- and MRP-mediated multidrug resistance in leukemia cell lines.

Yu-Ping Gong1, Ting Liu, Yong-Qian Jia, Li Qin, Cheng-Qi Deng, Ren-Yang Ou Yang.   

Abstract

Drug resistance is a major cause of the failure of anticancer chemotherapy. Multidrug resistance is often caused by overexpression of the P-glycoprotein (Pgp) or the multidrug resistance-related protein (MRP). In the present study, we compared daunorubicin (DNR) accumulation, subcellular distribution, and the effect of modulators on drug accumulation and subcellular distribution in the Pgp-expressing K562 cell line and the MRP-expressing HL60 cell line using reverse-transcriptase polymerase chain reaction, MTT (3-[4, 5-dimethylthiazol-z-yl]-2,5-diphenyltetrazolium bromide) drug cytotoxicity assay, fluorocytometry, and confocal laser scanning microscopy. The 2 resistant cell lines exhibit similar levels of resistance to DNR and decreased drug accumulation. Altered drug subcellular distribution in the resistant cell lines compared to that in the sensitive cell lines was shown and, moreover, differences in drug distributions between the 2 resistant cell lines were found. DNR fluorescence in the resistant HL60 cell line was distributed into punctate regions in the cytoplasm; the nucleus and other cytoplasm were almost negative. In contrast, the resistant K562 cells showed a bright fluorescent signal located in the peripheral cytoplasm and perinuclear region; the nucleus and other cytoplasmic regions showed no signal. Use of the modulator verapamil increased drug accumulation and restored the altered subcellular distribution of the drug in the 2 resistant cell lines. The Golgi apparatus inhibitor brefeldin A had similar action in the resistant HL60 line but had little effect in the resistant K562 line. Therefore, our study suggested that there were differences between the 2 resistant cell lines in the compartments sequestering DNR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11939261     DOI: 10.1007/BF02982020

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  23 in total

1.  Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells.

Authors:  A Calcabrini; S Meschini; A Stringaro; M Cianfriglia; G Arancia; A Molinari
Journal:  Histochem J       Date:  2000-10

2.  Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line.

Authors:  Y Gong; Y Wang; F Chen; J Han; J Miao; N Shao; Z Fang; R Ou Yang
Journal:  Leuk Res       Date:  2000-09       Impact factor: 3.156

3.  Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells.

Authors:  M C Willingham; N D Richert; M M Cornwell; T Tsuruo; H Hamada; M M Gottesman; I H Pastan
Journal:  J Histochem Cytochem       Date:  1987-12       Impact factor: 2.479

Review 4.  Biochemistry of multidrug resistance mediated by the multidrug transporter.

Authors:  M M Gottesman; I Pastan
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

5.  Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs.

Authors:  C E Grant; G Valdimarsson; D R Hipfner; K C Almquist; S P Cole; R G Deeley
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

6.  Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.

Authors:  C H Versantvoort; H J Broxterman; H M Pinedo; E G de Vries; N Feller; C M Kuiper; J Lankelma
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

7.  Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution.

Authors:  L M Breuninger; S Paul; K Gaughan; T Miki; A Chan; S A Aaronson; G D Kruh
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

8.  Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug.

Authors:  T McGrath; M S Center
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701

9.  Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.

Authors:  A Seidel; M Hasmann; R Löser; A Bunge; B Schaefer; I Herzig; K Steidtmann; M Dietel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 10.  Brefeldin A: insights into the control of membrane traffic and organelle structure.

Authors:  R D Klausner; J G Donaldson; J Lippincott-Schwartz
Journal:  J Cell Biol       Date:  1992-03       Impact factor: 10.539

View more
  4 in total

1.  Isothiocyanate-drug interactions in the human adenocarcinoma cell line Caco-2.

Authors:  Katarzyna Lubelska; Irena Misiewicz-Krzemińska; Małgorzata Milczarek; Jolanta Krzysztoń-Russjan; Elżbieta Anuszewska; Karolina Modzelewska; Katarzyna Wiktorska
Journal:  Mol Cell Biochem       Date:  2012-04-18       Impact factor: 3.396

2.  Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.

Authors:  Jia-Yin Yang; Hua-You Luo; Qi-Yuan Lin; Zi-Ming Liu; Lu-Nan Yan; Ping Lin; Jie Zhang; Shong Lei
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

3.  Applications of daunorubicin-loaded PLGA-PLL-PEG-Tf nanoparticles in hematologic malignancies: an in vitro and in vivo evaluation.

Authors:  Wen Bao; Ran Liu; Guohua Xia; Fei Wang; Baoan Chen
Journal:  Drug Des Devel Ther       Date:  2019-04-08       Impact factor: 4.162

4.  Reversion of p-glycoprotein-mediated multidrug resistance in human leukemic cell line by diallyl trisulfide.

Authors:  Qing Xia; Zhi-Yong Wang; Hui-Qing Li; Yu-Tao Diao; Xiao-Li Li; Jia Cui; Xue-Liang Chen; Hao Li
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-12       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.